12 
headings — namely, Institution, NIH, and Complii»'ce — with 
responsibilities listed under appropriate subheadings; 
• that application of the Guidelines extend to all recombinant DNA 
research done at institutions that receive NIH funding for 
recombinant DNA research; 
• that all recombinant DNA research at NIH-funded institutions, 
irrespective of the projects’ source of funds, be reviewed and 
approved by the Institutional Biosafety Committee (IBC); 
• that the authority be delegated from NIH to the IBC for an 
independent assessment of the safety standards applied, and that 
Committee approval be sufficient for the research to proceed; 
• that all research protocols reviewed and approved by the IBC be 
registered with ORDA-NIH and that ORDA would review all actions 
to ensure compliance with the NIH Guidelines (except for 
projects under the aegis of other Federal agencies); 
• that the institution assume responsibility for modifying the 
research protocol as recommended by NIH when NIH has found 
it in violation of the Guidelines. 
In sura, all recombinant DNA research in institutions receiving 
NIH funding shall be reviewed and approved by the local IBC and 
registered at NIH or other funding Federal agency. Authority 
for approval has been delegated to the local biosafety committee. 
Appr »vals are subject to subsequent NIH review to ensure compliance 
wi’ the NIH Guidelines, but investigators will not need approval 
[513] 
